fludarabine has been researched along with Thrombopenia in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (25.00) | 18.2507 |
| 2000's | 21 (43.75) | 29.6817 |
| 2010's | 11 (22.92) | 24.3611 |
| 2020's | 4 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, J; Cheng, H; Gao, X; Jiao, J; Li, D; Li, W; Li, Z; Liu, H; Ma, Y; Qin, Y; Sang, T; Sang, W; Shi, M; Song, X; Sun, C; Sun, H; Sun, K; Wang, Y; Wu, M; Xu, K; Xu, L; Yan, D; Yan, Z; Yang, J; Yao, M; Zeng, L; Zhang, B; Zheng, J; Zhu, F | 1 |
| Chen, A; Hayes-Lattin, B; Maziarz, RT; Murphree, C; Nagle, SJ; Nemecek, E; Raess, PW; Schachter, L | 1 |
| Bosch, F; Böttcher, S; Foà, R; Ilhan, O; Kisro, J; Leblond, V; Mahé, B; Mikuskova, E; Osmanov, D; Perretti, T; Reda, G; Robinson, S; Stilgenbauer, S; Tausch, E; Trask, P; Turgut, M; Van Hoef, M; Wójtowicz, M | 1 |
| Illés, Á; Szász, R; Telek, B | 1 |
| Bajwa, RP; Rose, MJ; Woods, G | 1 |
| Abella, E; Abrisqueta, P; Bobillo, S; Bosch, F; Calvo, X; Carbonell, F; Constants, M; Delgado, J; Escoda, L; Ferrà, C; Ferrer, S; García-Marco, JA; González, M; González, Y; González-Barca, E; Jarque, I; Montoro, JB; Montserrat, E; Monzó, E; Muntañola, A; Terol, MJ; Villamor, N | 1 |
| Beckers, MM; Daenen, S; Doorduijn, JK; Doreen Te Raa, G; Eldering, E; Kater, AP; Lankheet, NA; Liu, RD; Luijks, DM; Slinger, E; Spiering, M; Tonino, SH; van Oers, MH | 1 |
| Davis, J; Haut, P; Hayashi, R; Kothari, A; Loechelt, BJ; Murray, L; Ngwube, A; Shenoy, S | 1 |
| Branagan, AR; Emmanouilides, C; Frankel, SR; Gregory, SA; Ioakimidis, L; Kimby, E; Lister, A; Matous, J; Morel, P; Patterson, CJ; Soumerai, JD; Treon, SP; Turnbull, B; Wasi, P | 1 |
| Ben-Bassat, I; Bonstein, L; Gafter-Gvili, A; Raanani, P; Ram, R; Shpilberg, O | 1 |
| Carney, D; Gill, S; Januszewicz, H; Prince, HM; Ritchie, D; Seymour, JF; Westerman, D; Wolf, M | 1 |
| Bahlis, NJ; Barr, PM; Cooper, BW; Dowlati, A; Fu, P; Gerson, SL; Horvath, N; Koc, ON; Lazarus, HM; Snell, MR | 1 |
| Abramson, J; Brown, JR; Dalton, V; Freedman, AS; Hochberg, E; Kuang, Y; McDonough, SM; Mikler, E; Neuberg, D; Reynolds, H; Ritz, J; Thompson, C; Werner, L | 1 |
| Baldini, L; Federico, M; Ferrario, A; Goldaniga, MC; Luminari, S; Mannina, D; Marcheselli, L; Mazza, P; Merli, F; Russo, M; Stelitano, C | 1 |
| Badoux, X; Burger, J; Estrov, Z; Faderl, S; Ferrajoli, A; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Parikh, SA; Wang, X; Wierda, WG | 1 |
| Cao, JN; Fan, Y; Gu, KS; Guo, Y; Hong, XN; Li, XQ; Liu, XJ; Wang, CF; Wu, XH; Zhang, J | 1 |
| Bloor, A; Bosch, F; Bühler, A; Chanan-Khan, AA; Coutré, S; Dreisbach, L; Ferrajoli, A; Frankfurt, O; Furman, RR; Gobbi, M; Gribben, JG; Hallek, M; Heerema, NA; Hillmen, P; Hurd, DD; Kimby, E; Mahadevan, D; Moutouh-de Parseval, L; Sekeres, MA; Shah, S; Stilgenbauer, S; Uharek, L; Wendtner, CM; Zhang, J | 1 |
| Ehlert, K; Fruehwald, MC; Groll, AH; Juergens, H; Rossig, C | 1 |
| Brettman, L; Cooper, MR; Freter, CE; Mercier, RJ; Mitchell, BS; Rai, KR; Santábarbara, P; Stadtmauer, EA; Wacker, B | 1 |
| Aulitzky, WE; Diehl, V; Engert, A; Hallek, M; Hensel, M; Herold, M; Hinke, A; Huhn, D; Klein, SK; Knauf, WU; Rehwald, U; Reiser, M; Schulz, H | 1 |
| Fernandez, MJ; Grau, E; Llopis, I; Pastor, E; Real, E | 1 |
| Aliff, TB; Frankel, SR; Horgan, D; Jurcic, JG; Kossman, SE; Lamanna, N; Maslak, PG; Scheinberg, DA; Weiss, MA | 1 |
| Buser, A; Gratwohl, A; Heim, D; Kostova, G; Passweg, J; Tichelli, A | 1 |
| Asaka, M; Ehira, N; Fukushima, A; Imamura, M; Kanamori, H; Masauzi, N; Minami, H; Musashi, M; Obara, S; Ogura, N; Tanaka, J; Tsutsumi, Y; Yamato, H | 1 |
| Hamasaki, Y; Hara, T; Ihara, K; Imayoshi, M; Ishii, E; Miyazaki, S; Muraoka, K | 1 |
| Batár, P; Telek, B; Uvardy, M | 1 |
| Bergmann, M; Brittinger, G; Busch, R; Döhner, H; Eichhorst, BF; Emmerich, B; Hallek, M; Hensel, M; Hopfinger, G; Jäger, U; Pasold, R; Schweighofer, C; Siehl, S; Steinbrecher, C; Stilgenbauer, S; Wendtner, CM | 1 |
| Brugiatelli, M; Federico, M; Liberati, M; Marcheselli, R; Merli, F; Orsucci, L; Pozzi, S; Sacchi, S; Tucci, A; Vallisa, D | 1 |
| Barr, P; Cooper, B; Creger, R; Fu, P; Hartman, P; Kane, D; Laughlin, M; Lazarus, H; Meyerson, H; Reyes, R; Stear, K; Tse, W | 1 |
| Chen, L; Lü, SQ; Ni, X; Song, XM; Wang, JM; Xu, XQ; Yang, JM; Zhang, WP | 1 |
| Bendandi, M; Cantagalli, F; Macchi, S; Mancino, A; Simoncelli, F; Stefanati, V; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL | 1 |
| Andreeff, M; Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Pierce, S; Robertson, B | 1 |
| Bruijn, JA; van Groningen, K; van Royen, EA; Wijermans, PW | 1 |
| Doorduijn, JK; Michiels, JJ | 1 |
| Woodcock, BE | 1 |
| Collins, KA; Davda, RK; Kitchens, CS | 1 |
| Falkson, CI; Falkson, G; Hocepied, AM | 1 |
| Hilgenfeld, E; Jäger, U; Knauf, WU; Mitterbauer, M; Wilfing, A | 1 |
| Frewin, RJ; Provan, D; Smith, AG | 1 |
| Berrebi, A; Klepfish, A; Shtarlid, M; Shvidel, L; Sigler, E | 1 |
| Kalaycio, M; Sen, K | 1 |
| Cantú, OE; Gómez-Almaguer, D; González-Llano, O; Hernández, NE; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ | 1 |
| Brittinger, G; Busch, R; Döhner, H; Emmerich, B; Fostitsch, HP; Franke, A; Freund, M; Hallek, M; Herold, M; Hiddemann, W; Knauf, W; Kröber, A; Kuse, R; Nerl, C; Schmitt, B; Schriever, F; Sezer, O; Thiel, E; Wendtner, CM; Wilhelm, M | 1 |
| Cortes, J; Giles, F; Kantarjian, H; Keating, M; Koller, C; Loscertales, J; O'Brien, S; Thomas, D | 1 |
| Rouger, P; Wautier, JL | 1 |
| Fox, RM; Grigg, AP; Seymour, JF; Szer, J | 1 |
| Albitar, M; Binet, JL; Brettman, L; Byrd, J; Flinn, I; Hillmen, P; Jain, V; Keating, MJ; Rai, KR; Santabarbara, P; Wacker, B | 1 |
| Bladé, J; Cervantes, F; Marín, P; Montserrat, E; Rozman, C; Rozman, M | 1 |
6 review(s) available for fludarabine and Thrombopenia
| Article | Year |
|---|---|
Reduced intensity transplantation for congenital amegakaryocytic thrombocytopenia: report of a case and review of the literature.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Blood Platelets; Congenital Bone Marrow Failure Syndromes; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infant; Melphalan; Methylprednisolone; Mucositis; Neutrophils; Thrombocytopenia; Transplantation Conditioning; Vidarabine | 2014 |
Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Complement Activation; Complement System Proteins; Cyclophosphamide; Cytokines; Drug Eruptions; Female; Fever; Humans; Leukopenia; Lymphoma, Mantle-Cell; Mitoxantrone; Risk Factors; Rituximab; Splenomegaly; Thrombocytopenia; Vidarabine | 2009 |
Late graft failure in FA--case report and review of the literature.
Topics: Antigens, CD34; Antineoplastic Agents; Child; Fanconi Anemia; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Humans; Neutrophils; Risk Factors; Thrombocytopenia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2012 |
Is there a place for 2-CDA in the treatment of B-CLL?
Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Thrombocytopenia; Vidarabine | 1997 |
[Drug-induced hemolytic anemia].
Topics: Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Cephalosporins; Cyclosporine; Hemolytic-Uremic Syndrome; Humans; Isoantibodies; Leukemia, Lymphocytic, Chronic, B-Cell; Methyldopa; Procainamide; Purpura, Thrombocytopenic; Quinine; Rho(D) Immune Globulin; Thrombocytopenia; Vidarabine | 2001 |
[Treatment with cyclosporin A of the anemia associated with chronic lymphatic leukemia].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclosporins; Erythropoiesis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Red-Cell Aplasia, Pure; T-Lymphocytes, Regulatory; Thrombocytopenia; Vidarabine | 1990 |
24 trial(s) available for fludarabine and Thrombopenia
| Article | Year |
|---|---|
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Topics: Adult; Aged; Anemia; Antigens, CD19; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; CD4-CD8 Ratio; Confidence Intervals; Cyclophosphamide; Cytokine Release Syndrome; Female; Glycolysis; Humans; Ifosfamide; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Progression-Free Survival; Receptors, Chimeric Antigen; Recurrence; T-Lymphocytes; Thrombocytopenia; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2020 |
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Pharmacological; Chlorambucil; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Non-Randomized Controlled Trials as Topic; Progression-Free Survival; Recurrence; Safety; Thrombocytopenia; Treatment Outcome; Vidarabine | 2021 |
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Neutropenia; Prospective Studies; Remission Induction; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2013 |
Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Administration Schedule; Fatigue; Female; Gene Expression Regulation, Leukemic; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Male; Middle Aged; Nausea; NF-kappa B; Pneumonia; Pyrimidines; Thiazoles; Thrombocytopenia; Treatment Outcome; Vidarabine | 2014 |
Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin.
Topics: Acute Disease; Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Melphalan; Myeloablative Agonists; Neutropenia; Prospective Studies; Risk; Siblings; Survival Analysis; Thrombocytopenia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2015 |
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Neutropenia; Pneumonia; Prospective Studies; Rituximab; Survival Rate; Thrombocytopenia; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Nervous System Diseases; Neutropenia; Opportunistic Infections; Pyrazines; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2009 |
A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.
Topics: Adult; Aged; Alanine Transaminase; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Rituximab; Thrombocytopenia; Vidarabine | 2010 |
Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Italy; Lymphoma, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Thrombocytopenia; Vidarabine; Young Adult | 2011 |
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Risk Factors; Rituximab; Smith-Magenis Syndrome; Thrombocytopenia; Vidarabine | 2011 |
Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Survival Rate; Thrombocytopenia; Treatment Outcome; Vidarabine; Vomiting | 2012 |
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites, Antineoplastic; Dose-Response Relationship, Immunologic; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Tumor Lysis Syndrome; Vidarabine | 2012 |
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic, T-Cell; Male; Neutropenia; Opportunistic Infections; Pilot Projects; Remission Induction; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Failure; Treatment Outcome; Vidarabine | 2002 |
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Cerebral Hemorrhage; Chills; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Fever; Humans; Immunotherapy; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Middle Aged; Neutropenia; Prospective Studies; Remission Induction; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2002 |
Cytopenia and hematopoietic recovery after low intensity conditioning transplants.
Topics: Adult; Female; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Survival Analysis; Thrombocytopenia; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2004 |
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Infections; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Male; Middle Aged; Remission Induction; Retrospective Studies; Thrombocytopenia; Vidarabine | 2006 |
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Gene Rearrangement; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; Rituximab; Thrombocytopenia; Time Factors; Treatment Outcome; Vidarabine | 2007 |
Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neovascularization, Pathologic; Thalidomide; Thrombocytopenia; Topotecan; Vascular Endothelial Growth Factor A; Vidarabine | 2007 |
A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Fatigue; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Sleep Wake Disorders; Thrombocytopenia; Vidarabine | 1996 |
Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases.
Topics: Adolescent; Adult; Ambulatory Care; beta-Thalassemia; Blood Component Transfusion; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Remission Induction; Survival Rate; Thrombocytopenia; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2000 |
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Male; Middle Aged; Neutropenia; Thrombocytopenia; Treatment Outcome; Vidarabine | 2001 |
Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia.
Topics: Aged; Anemia; Antineoplastic Agents; Cyclosporine; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Splenectomy; Thrombocytopenia; Vidarabine | 2001 |
Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prognosis; Recurrence; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Vidarabine | 2002 |
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Demography; Humans; Immunocompromised Host; Infections; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Failure; Treatment Outcome; Vidarabine | 2002 |
18 other study(ies) available for fludarabine and Thrombopenia
| Article | Year |
|---|---|
Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bone Marrow; Combined Modality Therapy; Cyclophosphamide; Female; Ferritins; Humans; Immunotherapy, Adoptive; Infections; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Retrospective Studies; Thrombocytopenia; Vidarabine; Young Adult | 2021 |
Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia, Focusing on Long Term Cytopenias Before and After the Era of Targeted Therapies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Targeted Therapy; Prognosis; Retrospective Studies; Rituximab; Survival Rate; Thrombocytopenia; Vidarabine | 2021 |
The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Hematologic Diseases; Humans; Leukemia, Lymphoid; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Pancytopenia; Prevalence; Retrospective Studies; Thrombocytopenia; Time Factors; Vidarabine | 2010 |
Immune thrombocytopenia induced by fludarabine successfully treated with rituximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2003 |
Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Drug Administration Schedule; Drug Resistance; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Pentostatin; Thrombocytopenia; Treatment Outcome; Vidarabine | 2003 |
Successful treatment of lymphoma with fludarabine combined with rituximab after immune thrombocytopenia induced by fludarabine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, Follicular; Male; Middle Aged; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2005 |
Successful bone marrow transplantation in a patient with c-mpl-mutated congenital amegakaryocytic thrombocytopenia from a carrier donor.
Topics: Bone Marrow Purging; Bone Marrow Transplantation; Child; Female; Heterozygote; Humans; Immunosuppressive Agents; Megakaryocytes; Point Mutation; Thrombocytopenia; Thrombopoietin; Vidarabine | 2005 |
[Successful combined treatment with rituximab and high dose immunoglobulin in a patient with chronic lymphocytic leukemia with fludarabine-induced severe immune thrombocytopenia].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunoglobulins; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myeloablative Agonists; Rituximab; Severity of Illness Index; Thrombocytopenia; Treatment Outcome; Vidarabine | 2005 |
[A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Survival Rate; Thrombocytopenia; Vidarabine | 2007 |
Factor VIII inhibitor prior to and during secondary acute nonlymphocytic leukemia in a patient with cured Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Blood Transfusion; Combined Modality Therapy; Cytarabine; Factor VIII; Female; Granulocyte Colony-Stimulating Factor; Hemophilia A; Hemorrhage; Hodgkin Disease; Humans; Immunologic Factors; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Mechlorethamine; Middle Aged; Neoplasms, Second Primary; Plasmapheresis; Prednisone; Procarbazine; Prothrombin; Remission Induction; Thrombocytopenia; Vidarabine; Vincristine | 1995 |
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Thrombocytopenia; Vidarabine | 1994 |
Kaposi's sarcoma in an HIV-negative CLL patient as the cause of thrombocytopenia.
Topics: Aged; Antineoplastic Agents; Biopsy; Blood Platelets; HIV Seronegativity; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Subsets; Radionuclide Imaging; Sarcoma, Kaposi; Skin; Technetium Compounds; Thrombocytopenia; Vidarabine | 1994 |
Effectiveness of fludarabine in end-stage prolymphocytic leukemia.
Topics: Aged; Anemia; Antigens, CD; Antineoplastic Agents; Blood Transfusion; Chlorambucil; Female; Humans; Immunophenotyping; Leukemia, Prolymphocytic; Neoplasm Staging; Splenectomy; Thrombocytopenia; Vidarabine | 1994 |
Cytopenia and fludarabine.
Topics: Aged; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Neutropenia; Thrombocytopenia; Vidarabine | 1993 |
Case report: fatal Staphylococcus aureus sepsis from single-donor platelet transfusion.
Topics: Aged; Antineoplastic Agents; Bacteremia; Blood Donors; Carcinoma, Squamous Cell; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Platelet Transfusion; Skin Neoplasms; Staphylococcal Infections; Staphylococcus aureus; Thrombocytopenia; Vidarabine | 1994 |
Myelodysplasia occurring after fludarabine treatment for chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Chromosomes, Human, Pair 8; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myelodysplastic Syndromes; Neutropenia; Thrombocytopenia; Trisomy; Vidarabine | 1997 |
Evans syndrome complicating fludarabine treatment for advanced B-CLL.
Topics: Anemia, Hemolytic; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Syndrome; Thrombocytopenia; Vidarabine | 1997 |
Evan's syndrome precipitated by fludarabine therapy in a case of CLL.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Female; Humans; Immune Tolerance; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Prednisone; Thrombocytopenia; Vidarabine | 1999 |